Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z.

Mol Cancer Ther. 2018 Sep 25. pii: molcanther.0508.2018. doi: 10.1158/1535-7163.MCT-18-0508. [Epub ahead of print]

PMID:
30254184
2.

The "Aging Factor" Eotaxin-1 (CCL11) Is Detectable in Transfusion Blood Products and Increases with the Donor's Age.

Hoefer J, Luger M, Dal-Pont C, Culig Z, Schennach H, Jochberger S.

Front Aging Neurosci. 2017 Dec 1;9:402. doi: 10.3389/fnagi.2017.00402. eCollection 2017.

3.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H.

Clin Cancer Res. 2018 Feb 15;24(4):927-938. doi: 10.1158/1078-0432.CCR-17-0989. Epub 2017 Nov 20.

PMID:
29158269
4.

Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support.

Hoefer J, Ulmer H, Kilo J, Margreiter R, Grimm M, Mair P, Ruttmann E; Innsbruck Liver-in-Heart-Failure Program.

J Thorac Cardiovasc Surg. 2017 Jun;153(6):1374-1382. doi: 10.1016/j.jtcvs.2017.01.053. Epub 2017 Feb 9.

PMID:
28274560
5.

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.

Hoefer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, Culig Z, Klocker H, Heidegger I.

Oncotarget. 2016 Sep 13;7(37):59781-59794. doi: 10.18632/oncotarget.10926.

6.

SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.

Handle F, Erb HH, Luef B, Hoefer J, Dietrich D, Parson W, Kristiansen G, Santer FR, Culig Z.

Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.

7.

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.

Puhr M, Hoefer J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z.

Oncogene. 2016 May 5;35(18):2322-32. doi: 10.1038/onc.2015.292. Epub 2015 Aug 10.

8.

Ultrasound-guided regional anesthesia for carotid endarterectomy induces early hemodynamic and stress hormone changes.

Hoefer J, Pierer E, Rantner B, Stadlbauer KH, Fraedrich G, Fritz J, Kleinsasser A, Velik-Salchner C.

J Vasc Surg. 2015 Jul;62(1):57-67. doi: 10.1016/j.jvs.2015.02.036. Epub 2015 May 5.

9.

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.

Puhr M, Hoefer J, Neuwirt H, Eder IE, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z.

Oncotarget. 2014 Dec 15;5(23):12043-56.

10.

Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2.

Tancevski I, Nairz M, Duwensee K, Auer K, Schroll A, Heim C, Feistritzer C, Hoefer J, Gerner RR, Moschen AR, Heller I, Pallweber P, Li X, Theurl M, Demetz E, Wolf AM, Wolf D, Eller P, Ritsch A, Weiss G.

EMBO Mol Med. 2014 Jun;6(6):810-20. doi: 10.1002/emmm.201303415. Epub 2014 Apr 6.

11.

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.

Hoefer J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z, Puhr M.

Endocr Relat Cancer. 2014 Jan 30;21(2):175-87. doi: 10.1530/ERC-13-0446. Print 2014 Apr.

12.

Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.

Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z.

Am J Pathol. 2012 Dec;181(6):2188-201. doi: 10.1016/j.ajpath.2012.08.011. Epub 2012 Oct 3.

13.

Surgery of a cyanotic heart defect in an 11-year-old boy with thrombocytopenic thrombocytopathy and severe anemia due to a GATA-1 defect: hemostatic therapy.

Hoefer J, Streif W, Kilo J, Grimm M, Berger G, Velik-Salchner C.

Klin Padiatr. 2012 Oct;224(6):382-5. doi: 10.1055/s-0032-1321875. Epub 2012 Aug 22.

PMID:
22915449
14.

PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.

Hoefer J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, Puhr M, Culig Z.

Am J Pathol. 2012 May;180(5):2097-107. doi: 10.1016/j.ajpath.2012.01.026. Epub 2012 Mar 23.

15.

Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.

Shariat SF, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT.

J Urol. 2011 Nov;186(5):2107-14. doi: 10.1016/j.juro.2011.06.048. Epub 2011 Sep 23.

PMID:
21944124
16.

Sphingosine-1-phosphate-dependent activation of p38 MAPK maintains elevated peripheral resistance in heart failure through increased myogenic vasoconstriction.

Hoefer J, Azam MA, Kroetsch JT, Leong-Poi H, Momen MA, Voigtlaender-Bolz J, Scherer EQ, Meissner A, Bolz SS, Husain M.

Circ Res. 2010 Oct 1;107(7):923-33. doi: 10.1161/CIRCRESAHA.110.226464. Epub 2010 Jul 29.

PMID:
20671234
17.

The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.

Tancevski I, Demetz E, Eller P, Duwensee K, Hoefer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, Huber J, Schgoer W, Van Eck M, Vanhoutte J, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A.

PLoS One. 2010 Jan 15;5(1):e8722. doi: 10.1371/journal.pone.0008722.

18.

The thyromimetic T-0681 protects from atherosclerosis.

Tancevski I, Wehinger A, Demetz E, Hoefer J, Eller P, Huber E, Stanzl U, Duwensee K, Auer K, Schgoer W, Kuhn V, Fievet C, Stellaard F, Rudling M, Foeger B, Patsch JR, Ritsch A.

J Lipid Res. 2009 May;50(5):938-44. doi: 10.1194/jlr.M800553-JLR200. Epub 2008 Dec 22.

19.

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.

Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M.

Circulation. 2008 May 6;117(18):2340-50. doi: 10.1161/CIRCULATIONAHA.107.739938. Epub 2008 Apr 21. Erratum in: Circulation. 2008 Jul 22;118(4):e81.

PMID:
18427132

Supplemental Content

Loading ...
Support Center